iPSC-MSC Progenitor Exosomes for Renal Cell Protection

The patent segments the mesenchymal stem cell system into two distinct components: the progenitor cells (which maintain high proliferative ability) and the exosomes (which carry the therapeutic function). By separating these functions, the system can use highly proliferative progenitor cells to continuously produce exosomes without suffering from the functional decline that occurs when using differentiated mesenchymal stem cells directly for therapy.

The patent applies preliminary action by using progenitor cells to pre-produce and secrete exosomes before the actual therapeutic administration. The progenitor cells are cultured to generate large quantities of exosomes, which are then collected and administered to patients. This allows the therapeutic effect to be delivered without requiring the presence of living mesenchymal stem cells, thereby avoiding their functional decline with passages.

The patent changes the key parameter of cell proliferation capacity by switching from using differentiated mesenchymal stem cells to using their undifferentiated progenitor cells. Progenitor cells exhibit significantly higher proliferative capacity and can be expanded to large numbers in culture, thereby enabling the production of sufficient exosome quantities for commercial applications while maintaining therapeutic effectiveness.

The patent uses progenitor cells as a renewable source to continuously copy and produce exosomes. The high proliferative capacity of progenitor cells allows for the expansion of cell cultures and subsequent large-scale production of exosomes, effectively copying the therapeutic substance in quantities suitable for commercial use without depleting the source cell population.

The patent extracts only the essential therapeutic component (exosomes) from the complex mesenchymal stem cell system and administers it separately. This eliminates the need for complex procedures like dialysis machines or organ transplantation surgery, while retaining the therapeutic benefits. The exosomes can be administered through simpler routes such as injection, significantly reducing treatment complexity.

The patent employs a disposable approach by using exosomes - stable, non-living therapeutic particles - instead of requiring long-term maintenance of living stem cells or expensive infrastructure like dialysis centers. The exosomes can be produced, formulated, and administered as a single-use therapeutic product, reducing ongoing costs and infrastructure requirements compared to traditional kidney failure treatments.